$CDNA News

CAREDX INC (NASDAQ:CDNA) Shows Perfect Minervini Trend Template and High Growth Momentum Setup

CareDx's 2021 Qui Tam Action Dismissed; No Monetary Payment Associated With Dismissal

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript

BTIG Maintains Buy on CareDx, Raises Price Target to $28

CareDx (NASDAQ:CDNA) Beats Q1 Estimates and Raises Full-Year Guidance, But Stock Slips

CareDx, Inc. 2026 Q1 - Results - Earnings Call Presentation

CareDx Files For Mixed Shelf; Size Not Disclosed

CareDx Strikes Agreement To Acquire Naveris For $160M Upfront Payment, $100M In Future Milestones

CareDx Raises FY2026 Sales Guidance from $420.000M-$444.000M to $447.000M-$465.000M vs $436.665M Est

CareDx Q1 Adj. EPS $0.34 Beats $0.13 Estimate, Sales $117.700M Beat $104.034M Estimate

CareDx Launches New Test That Matches Organ Donors and Patients in Under 3 Hours, Unveils AlloSeq Nano With 45-Minute Prep and Faster, More Accurate Transplant Matching

CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results

CareDx Sharpens Focus On Core Testing Services

CareDx shares are trading higher after the company announced it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific. The company reported a year-over-year increase in preliminary Q1 revenue results.

CareDx shares are trading higher after the company announced it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific. The company reported a year-over-year increase in preliminary Q1 revenue results.

CareDx Signs Agreement With EuroBio Scientific To Divest Lab Products Operations For $170M In Cash; Reports Preliminary Q1 Revenue ~$118M, Up 39% YoY

CareDx Announces Launch Of AI-Powered Clinical Data And Analytics Platform VANTx

BTIG Maintains Buy on CareDx, Raises Price Target to $26

Wells Fargo Maintains Equal-Weight on CareDx, Raises Price Target to $21

CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript